Editas Medicine, Inc.

NasdaqGS:EDIT Stock Report

Market Cap: US$99.9m

Editas Medicine Future Growth

Future criteria checks 0/6

Editas Medicine is forecast to grow earnings and revenue by 7.7% and 0.7% per annum respectively. EPS is expected to grow by 19.5% per annum. Return on equity is forecast to be -225.9% in 3 years.

Key information

7.7%

Earnings growth rate

19.5%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate0.7%
Future return on equity-225.9%
Analyst coverage

Good

Last updated16 Dec 2024

Recent future growth updates

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

Recent updates

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

Nov 20
Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Nov 06
Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Sep 26
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine: A Risk/Reward Worth Considering

Sep 25

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Aug 23
Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15
New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10
Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Sep 13
We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Aug 23

Editas Medicine Q2 2022 Earnings Preview

Aug 02

Baisong Mei joins Editas Medicine as Chief Medical Officer

Jul 18

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Jun 12
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Jun 06

Earnings and Revenue Growth Forecasts

NasdaqGS:EDIT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202610-164-154-15411
12/31/202521-145-179-15917
12/31/202443-228-140-12817
9/30/202462-211-191-182N/A
6/30/202467-193-172-165N/A
3/31/202469-166-151-146N/A
12/31/202378-153-137-132N/A
9/30/202325-195-156-152N/A
6/30/202319-206-169-165N/A
3/31/202323-219-168-164N/A
12/31/202220-220-181-177N/A
9/30/202226-201-176-170N/A
6/30/202232-184-171-162N/A
3/31/202226-186-174-164N/A
12/31/202126-193-172-164N/A
9/30/202124-214-176-169N/A
6/30/202181-167-189-183N/A
3/31/202192-135-180-175N/A
12/31/202091-116-187-180N/A
9/30/202092-91-106-99N/A
6/30/202033-132-79-71N/A
3/31/202024-142-73-66N/A
12/31/201921-134-47-41N/A
9/30/201914-121-86-80N/A
6/30/201925-103-66-61N/A
3/31/201930-108-57-52N/A
12/31/201832-110-50-46N/A
9/30/201829-121-76-72N/A
6/30/201821-132N/A-92N/A
3/31/201817-120N/A-102N/A
12/31/201714-120N/A-9N/A
9/30/201711-124N/A2N/A
6/30/20176-118N/A13N/A
3/31/20176-111N/A29N/A
12/31/20166-97N/A-50N/A
9/30/20166-71N/A-45N/A
6/30/20166-57N/A-39N/A
3/31/20162-86N/A-9N/A
12/31/20152-73N/A-5N/A
9/30/20151-66N/A-1N/A
6/30/20150-62N/A9N/A
3/31/2015N/A-17N/A-13N/A
12/31/2014N/A-14N/A-9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EDIT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EDIT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EDIT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EDIT's revenue (0.7% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: EDIT's revenue (0.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EDIT is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 05:47
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Editas Medicine, Inc. is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Joel BeattyBaird
Huidong WangBarclays